Combination of AstraZeneca and Sputnik Light showed high antibody growth, preliminary study data shows

Russian Direct Investment Fund (RDIF) released today preliminary results based on the observations of the first 20 study volunteers who received a heterologous vaccination schedule, that is, patients who combined inoculants from different laboratories. The first component used was the AstraZeneca vaccine and the second was Sputnik Light, that is, component 1 of the Russian vaccine. The interval between doses was 29 days.

Based on the results of the interim analysis, 85% of volunteers experienced a fourfold increase or more in neutralizing antibodies against the peak protein (S protein) of the SARS-CoV-2 virus on day 57 of follow-up. Research in Azerbaijan started in February 2021 and has 100 volunteers.

The Russian Direct Investment Fund, the companies AstraZeneca and R-PHARM announced preliminary data for the virus from the combined application of the vaccine AstraZeneca (jointly developed with the University of Oxford) and the first component of the Russian vaccine Sputnik V, the Sputnik Light drug based on human adenovirus serotype 26, obtained in a clinical study in the Republic of Azerbaijan.

Interim analysis of data in Azerbaijan also demonstrated the production of antibodies against the spike protein (S protein) of the SARS-CoV-2 virus in 100% of volunteers, as well as high rates of safety from combined use. medication: no there were no serious adverse events and no cases of coronavirus infection after vaccination. In addition to Azerbaijan, the clinical study of the vaccine combination is being implemented as part of the global program in the United Arab Emirates and Russia.

Sputnik Light is the first component of the Sputnik V vaccine. According to the results of the Gamaleya Institute, the effectiveness rate is around 80% and it maintains protection against new variants of COVID-19.

Argentina was the first Latin American state to approve the use of Sputnik V, as well as the first country in the region to start production of the Russian vaccine. The recording was made by means of an emergency use authorization. Vaccination with the Russian drug began in the country on December 29, 2020. RDIF and its partners carried out a technology transfer for the laboratories in Richmond, and Local production of Sputnik V started in April 2021.

In the Argentina almost 11 million people received component 1 of the Sputnik vaccine, 9.77 million were produced in Russia and the remainder, about 1.17 million, were produced in the country by the Richmond laboratory.

In the country, different trials have been launched to study the interchangeability of sera in recent months. One is carried out in the city of Buenos Aires by the Ministry of Health of Buenos Aires. It is carried out with people who received the first dose of Sputnik V more than 30 days ago, who are over 21 years old and who wish to participate voluntarily. The efficacy and safety of different vaccines that already have an emergency use authorization by the Argentinian regulatory agency, ANMAT, are being tested.

That of Azerbaijan is a clinical study of vaccine combination carried out within the framework of a global program that also includes the United Arab Emirates, Russia and, in a short time, Belarus will also join.

Since the start of the campaign, the country has received 67,508,045 vaccines. Of this total, 28,856,000 correspond to the Sinopharm laboratory, 14.234.820 pertenecen a Sputnik V (9.775.655 del componente 1, y 4.459.165 del componente 2), y 3.129.125 a Sputnik V producidas en Argentina por Laboratorio Richmond (1.179.625 del primer componente, y 1.949.500 del second).

From the company AstraZeneca 16,966,900 doses were received (580,000 from Covishield; 1,944,000 received via the COVAX mechanism, 13,200,500 from AstraZeneca and Oxford, the active ingredient of which was produced in Argentina; and 1,242,400 donated by Spain). Meanwhile, 3,500,000 correspond to Moderna donated by the United States, 600,000 to CanSino and 421,200 to Pfizer.

According to the Public Vaccination Observatory, this morning, 55,269,629 doses were distributed throughout the country, while the requests totaled 50,910,055. In turn, 64.3% of the population received a single dose. (29,430,580 people) and 46.8% completed the two-dose schedule (21,359,871 people).

KEEP READING: